BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

693 related articles for article (PubMed ID: 26520640)

  • 21. Prognostic factors and outcome of surgically treated patients with brain metastases of non-small cell lung cancer.
    She C; Wang R; Lu C; Sun Z; Li P; Yin Q; Liu Q; Wang P; Li W
    Thorac Cancer; 2019 Feb; 10(2):137-142. PubMed ID: 30485664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gamma Knife radiosurgery for brain metastases from pulmonary large cell neuroendocrine carcinoma: a Japanese multi-institutional cooperative study (JLGK1401).
    Kawabe T; Yamamoto M; Sato Y; Yomo S; Kondoh T; Nagano O; Serizawa T; Tsugawa T; Okamoto H; Akabane A; Aita K; Sato M; Jokura H; Kawagishi J; Shuto T; Kawai H; Moriki A; Kenai H; Iwai Y; Gondo M; Hasegawa T; Yasuda S; Kikuchi Y; Nagatomo Y; Watanabe S; Hashimoto N
    J Neurosurg; 2016 Dec; 125(Suppl 1):11-17. PubMed ID: 27903179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.
    Okuma Y; Hosomi Y; Nagamata M; Yamada Y; Sekihara K; Kato K; Hishima T; Okamura T
    Anticancer Res; 2013 Nov; 33(11):5057-64. PubMed ID: 24222150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients.
    Hsiao SH; Lin HC; Chou YT; Lin SE; Kuo CC; Yu MC; Chung CL
    Lung Cancer; 2013 Sep; 81(3):455-461. PubMed ID: 23871711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gamma knife radiosurgery for treatment of cerebral metastases from non-small-cell lung cancer.
    Motta M; del Vecchio A; Attuati L; Picozzi P; Perna L; Franzin A; Bolognesi A; Cozzarini C; Calandrino R; Mortini P; di Muzio N
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e463-8. PubMed ID: 21530098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determinants of survival in advanced non--small-cell lung cancer in the era of targeted therapies.
    Bauml J; Mick R; Zhang Y; Watt CD; Vachani A; Aggarwal C; Evans T; Langer C
    Clin Lung Cancer; 2013 Sep; 14(5):581-91. PubMed ID: 23827517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gamma knife radiosurgery for the management of cerebral metastases from non-small cell lung cancer.
    Bowden G; Kano H; Caparosa E; Park SH; Niranjan A; Flickinger J; Lunsford LD
    J Neurosurg; 2015 Apr; 122(4):766-72. PubMed ID: 25658792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer.
    Tomasini P; Serdjebi C; Khobta N; Metellus P; Ouafik L; Nanni I; Greillier L; Loundou A; Fina F; Mascaux C; Barlesi F
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term survival in patients with synchronous, solitary brain metastasis from non-small-cell lung cancer treated with radiosurgery.
    Flannery TW; Suntharalingam M; Regine WF; Chin LS; Krasna MJ; Shehata MK; Edelman MJ; Kremer M; Patchell RA; Kwok Y
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):19-23. PubMed ID: 18280058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.
    Byeon S; Ham JS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Med Oncol; 2016 Aug; 33(8):97. PubMed ID: 27447711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
    Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
    Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive factors of early distant brain failure after gamma knife radiosurgery alone in patients with brain metastases of non-small-cell lung cancer.
    Na YC; Jung HH; Kim HR; Cho BC; Chang JW; Park YG; Chang WS
    J Neurooncol; 2017 Apr; 132(2):333-340. PubMed ID: 28074321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene.
    Krawczyk P; Kowalski DM; Krawczyk KW; Szczyrek M; Mlak R; Rolski A; Szudy A; Kieszko R; Winiarczyk K; Milanowski J; Krzakowski M
    Oncol Rep; 2013 Sep; 30(3):1463-72. PubMed ID: 23783797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gamma knife radiosurgery in non small cell lung cancer patients with brain metastases: treatment results and prognostic factors.
    Abacioglu U; Caglar H; Atasoy BM; Abdulloev T; Akgun Z; Kilic T
    J BUON; 2010; 15(2):274-80. PubMed ID: 20658721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases.
    Lee HL; Chung TS; Ting LL; Tsai JT; Chen SW; Chiou JF; Leung HW; Liu HE
    Radiat Oncol; 2012 Oct; 7():181. PubMed ID: 23110940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
    Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N
    J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Timing of Whole Brain Radiotherapy on Survival of Patients with EGFR-mutated 
Non-small Cell Lung Cancer and Brain Metastases].
    Liu G; Zhang X; Tian C; Xia G; Liu P; Zhang Q; Li X; Zhang H; Qin N; Wang J; Zhang S
    Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):501-7. PubMed ID: 27561798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prolonged survival of patients with EGFR-mutated non-small cell lung cancer with solitary brain metastases treated with surgical resection of brain and lung lesions followed by EGFR TKIs.
    Gui Q; Liu J; Li D; Xu C
    World J Surg Oncol; 2017 Oct; 15(1):184. PubMed ID: 29037198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.